Clinical trial
A Phase I Dose Finding and Proof-of-concept Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Combination With Standard Dose Cytarabine and Daunorubicin for Older Patients With Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
NCT01463046 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Dose Finding and Proof-of-concept Study of the Histone Deacetylase Inhibitor Panobinostat (LBH589) in Combination With Standard Dose Cytarabine and Daunorubicin for Older Patients With Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome
- Lead sponsor
- University of California, San Francisco
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2012
- Completion date
- December 31, 2018
- Enrollment
- 29 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
acute myeloid leukemia, advanced myelodysplastic syndrome